Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

  • carrivechio carrivechio Dec 16, 2012 11:24 AM Flag

    Metastatic Cancer - 51 billion dollar market

    Search: Metastasis discovery may improve cancer treatment

    "The spread of cancer, called metastasis, is a defining characteristic of the disease. Metastasis causes an estimated 90 percent of cancer deaths. It starts when malignant cells activate an embryonic process that creates a kind of cell which can move around the body, according to the study, published Thursday in "cancer cell".

    Understanding this process is essential to stopping it, the study stated. A drug developed from this hypothesis would address a market for targeted cancer therapies estimated to exceed $50 billion by 2015."

    " Chemotherapy interferes with cell division, so it mostly kills rapidly dividing cancer cells but also other normal cells that rapidly divide, such as those in hair follicles and the gut. So researchers are looking for specific molecular differences between cancer cells and normal cells to target.

    The market for such targeted cancer therapies, as they're known, is expected to reach $51 billion annually by 2015, according to a 2010 report from Decision Resources. That's double the 2008 figure of $25 billion."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Reposted for the benefit of new readers:

      Search: Metastasis discovery may improve cancer treatment

      "The spread of cancer, called metastasis, is a defining characteristic of the disease. Metastasis causes an estimated 90 percent of cancer deaths. It starts when malignant cells activate an embryonic process that creates a kind of cell which can move around the body, according to the study, published Thursday in "cancer cell".

      Understanding this process is essential to stopping it, the study stated. A drug developed from this hypothesis would address a market for targeted cancer therapies estimated to exceed $50 billion by 2015."

      " Chemotherapy interferes with cell division, so it mostly kills rapidly dividing cancer cells but also other normal cells that rapidly divide, such as those in hair follicles and the gut. So researchers are looking for specific molecular differences between cancer cells and normal cells to target.

      The market for such targeted cancer therapies, as they're known, is expected to reach $51 billion annually by 2015, according to a 2010 report from Decision Resources. That's double the 2008 figure of $25 billion."

      • 1 Reply to carrivechio
      • Re-posted once again for the benefit of the new viewers to this message board:

        Search: Metastasis discovery may improve cancer treatment

        "The spread of cancer, called metastasis, is a defining characteristic of the disease. Metastasis causes an estimated 90 percent of cancer deaths. It starts when malignant cells activate an embryonic process that creates a kind of cell which can move around the body, according to the study, published Thursday in "cancer cell".

        Understanding this process is essential to stopping it, the study stated. A drug developed from this hypothesis would address a market for targeted cancer therapies estimated to exceed $50 billion by 2015."

        " Chemotherapy interferes with cell division, so it mostly kills rapidly dividing cancer cells but also other normal cells that rapidly divide, such as those in hair follicles and the gut. So researchers are looking for specific molecular differences between cancer cells and normal cells to target.

        The market for such targeted cancer therapies, as they're known, is expected to reach $51 billion annually by 2015, according to a 2010 report from Decision Resources. That's double the 2008 figure of $25 billion."

    • Understanding this (metastatic) process is essential to stopping it, the study stated.

      In a current paper by the same Dr Watson who won a nobel for his DNA work, he cites tumor hypoxia as a mediator of metastasis. And relates high antioxidant levels of RAS tumors as enabling them to resist chemo and radiation.

      Another interesting study found beta blockers were able to restrict/inhibit the development of mets even tho they did not inhibit growth of locoregional tumors in the same patients. I'm only a layman but to me it's further evidence that mets are a distinct and more vulnerable target. Corroborating what we are discovering so far in our own trial.

    • Duuude you're an idiot (Although idiots occasionally make money) the 51B market is for TARGETED therapies not metastatic disease. The article was poorly written but if your READ it, it does say that the 51B is for TARGETED therapies (which is consistent with a GSK report I've read) and most of that would be FIRST LINE treatment and much of the rest would be for FIRST line metastatic disease. The entire market for a patient population which is both SECOND line AND METASTATIC treatment is about 5% or less of the 51B.

      • 3 Replies to rationalthought11
      • So...Only 5% of 51 Billion or 2.5 Billion Market for an indication that was not even on the drawing board...Says ThinkingRat... With H&N,Pancreatic,Ovarian,Lung,Prostate,Colorectal,and Breast,this company had a Full Plate! Now ThinkingRat throws in Another lousy 2.5 Billion Market on top of what was already looking to be a Huge Market...As in Billions and Billions and Billions...Please ThinkingRat,No More...Lets not take over the entire Oncology Market...No single company should be that Huge. Just think of all the little investers that will be transformed into Evil Millionaires. ThinkingRat...Say it Ain't So...

        Sentiment: Strong Buy

      • "The article was poorly written but if your READ it, it does say that the 51B is for TARGETED therapies ..."

        You should take the time to read the article, particularly where it states that "There's certain tumors that locally can be problems, but if they don't metastasize, we don't even call them cancer".

        And with that qualifier, the article went on to state:

        "So researchers are looking for specific molecular differences between cancer cells and normal cells to target.

        The market for such targeted cancer therapies, as they're known, is expected to reach $51 billion annually by 2015, according to a 2010 report from Decision Resources. That's double the 2008 figure of $25 billion. "

        I suggest that you understand that ONCY has identified those molecular differences between cancer cells and normal cells, and is able to specifically target those cancer cells, without affecting normal cells.

        Therefore ONCY's reovirus targets metastatic cancer, which is estimated to be a $51 Billion market by 2015.

      • Yes Paul - your irrational posts always seem to overlook the obvious, especially those appearing in MF, such as the obvious following statement appearing in the article:

        "There's certain tumors that locally can be problems, but if they don't metastasize, we don't even call them cancer."

        By extension, metastatic "cancer" & the market for metastatic/targeted cancer therapies is estimated to exceed $40 billion by 2015.

        Search: Metastasis discovery may improve cancer treatment

        "The spread of cancer, called metastasis, is a defining characteristic of the
        disease. Metastasis causes an estimated 90 percent of cancer deaths. It starts
        when malignant cells activate an embryonic process that creates a kind of cell
        which can move around the body, according to the study, published Thursday in
        "cancer cell".

        Understanding this process is essential to stopping it, the study stated. A drug
        developed from this hypothesis would address a market for targeted cancer
        therapies estimated to exceed $50 billion by 2015."

        " Chemotherapy interferes with cell division, so it mostly kills rapidly
        dividing cancer cells but also other normal cells that rapidly divide, such as
        those in hair follicles and the gut. So researchers are looking for specific
        molecular differences between cancer cells and normal cells to target.

        The market for such targeted cancer therapies, as they're known, is expected to
        reach $51 billion annually by 2015, according to a 2010 report from Decision
        Resources. That's double the 2008 figure of $25 billion."

    • irrational thought,

      This is what the prescibing information sheet (package insert) for Erbitux says about its ability to treat Kras cancers

      "Erbitux is not effective for the treatment of K-Ras mutation-positive cancer"

      If you look at the break out for H&N cancers, cetuximab plus chemo dose worse than chemo alone for Kras mutant cancers.

      Could you give some sign that you understand what is going on here? Or are you getting paid in pita bread and red sauce to spread misinformation?

      You asked me to post something useful. Until we have more data, I probably won't offer any comments. I will simply continue to correct people that mangle the facts.

      Sentiment: Strong Buy

      • 1 Reply to nomenome91
      • mouthy punk ain't ya? Kras mutations are present in between 16 and 40 percent of h and n cancers, although there are recent studies that indicate a much lower rate leaving Erbitux with the bulk of the market. Keeping it real for ya smart guy. as for signs about knowing what is going on you ain't doin so good.

        for the record I am agnostic on whether reo will be found to be effective but I don't make decisions regarding my hard earned cash without getting as much info as possible like some folks here seem to do. And the data is very marginal which you would see if you we're able to take an objective look at it.

    • Yahoo is not posting my response which only stated that ONCY announced very positive interim data in a UK translational clinical trial investigating intravenous administration of Reolysin in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.

    • When all is said and done, I think the mets market will be what propels ONCY. There is no viable treatment for mets and mets are what usually end up killing the patient. If the results from the 12 week scans are as good as we expect them to be, 2013 will be a great year for investor and patient. Can't come soon enough as one of my relatives could benefit from this treatment, but can't since it's not officially on the market yet. I just hope he's able to survive through the FDA approval process.

    • ONCY has already demonstrated that reovirus is able to "purge" embryonic cancer cells in vitro and has been granted a patent for this process.

      In vitro purging be extension demonstrates in vivo activity, which is now beginning to be confirmed empirically by the results from ONCY's clinical trials.

 
ONCY
0.6099+0.0099(+1.65%)10:22 AMEDT